The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease
Extracorporeal photopheresis (ECP) is commonly used either in combination with infliximab or monotherapy as second- or third-line therapy for patients with graft-versus-host disease (GvHD) who are dependent or refractory to steroids. Ioanna Sakellari et al. from George Papanikolaou Hospital, Thessaloniki, Greece, prospectively evaluated the safety and efficacy of ECP as a second- or third-line treatment in patients with GvHD treated at their center. The study was published ahead of print in the Journal of Clinical Apheresis.
The primary endpoints of the study included overall response rate (ORR) and overall survival (OS). Secondary endpoints were incidences of infections during early post-transplant period and transplant-related mortality (TRM).
Patients and characteristics:
- Patients received hematopoietic stem cell transplantation according to the standard EBMT indications
- N = 21 patients with grade III-IV acute GvHD, median age = 44 years (range, 22–67)
- N = 88 patients with extensive chronic GvHD, median age = 35 years (range, 19–64)
- Eight patients receiving ≤ 4 ECP sessions were excluded from study
Key findings:
Acute GvHD
- ORR: 84%; of these acute GvHD patients 15 achieved partial whereas one complete response
- Immunosuppressive therapy was reduced in 11/19 patients
- 1-year TRM: 17.6%
- 1-year TRM associated with steroid refractoriness and lack of response to therapy
- 1-year OS: 52.5%
- 1-year OS showed significant association with higher number of ECP sessions
Chronic GvHD
- ORR: 73%; of these chronic GvHD patients, 35 achieved complete and 25 partial response
- Cutaneous sclerosis manifestations showed correlation with higher response rates
- 5-year TRM: 24.1%
- 5-year TRM was correlated only with a number of ECP sessions
- 5-year OS: 64.5%
- 5-year OS correlated with number of ECP sessions and cutaneous manifestations
In summary, this study indicates that ECP is safe and effective for the treatment of GvHD, especially if it is administered early. The study group stated that “because available data do not favor one agent for second-line therapy of GVHD above another, our results suggest that its choice should be based on potential toxicity, physician experience, and availability of the treatment.”
References